Advice
Following an abbreviated submission
choriogonadotropin alfa 250 mcg/0.5 ml pre-filled syringe (Ovitrelle) is accepted for use in NHS Scotland for the treatment of anovulatory or oligo-ovulatory women, where the use of this preparation is appropriate.
Unlike the vial formulation available previously it does not require reconstitution, and the cost per dose is the same.
This replaces advice previously issued by the Scottish Medicines Consortium for Ovitrelle in May 2006 following a non-submission.
Download detailed advice29KB (PDF)
Medicine details
- Medicine name:
- choriogonadotropin alfa 250Â mcg/0.5Â ml pre-filled syringe (Ovitrelle)
- SMC ID:
- 264/06
- Indication:
- Anovulatory or oligo-ovulatory women
- Pharmaceutical company
- Serono Ltd
- BNF chapter
- Endocrine system
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 09 October 2006